Newamsterdam Pharma Stock Performance
| NAMS Stock | 19.85 0.95 4.57% |
On a scale of 0 to 100, NewAmsterdam Pharma holds a performance score of 9. The company secures a Beta (Market Risk) of 2.19, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, NewAmsterdam Pharma will likely underperform. Please check NewAmsterdam Pharma's downside variance, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether NewAmsterdam Pharma's current price movements will revert.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in NewAmsterdam Pharma are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak primary indicators, NewAmsterdam Pharma unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (4.57) | Five Day Return (3.41) | Year To Date Return 66.11 | Ten Year Return 87.05 | All Time Return 87.05 |
Last Split Factor 1:1 | Last Split Date 2022-11-23 |
1 | NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 09/06/2024 |
2 | Acquisition by Louise Kooij of 45000 shares of NewAmsterdam Pharma subject to Rule 16b-3 | 09/27/2024 |
3 | NewAmsterdam Pharma CAO Louise Frederika Kooij Sells 45,000 Shares | 10/03/2024 |
4 | Disposition of 15000 shares by Davidson Michael H. of NewAmsterdam Pharma at 11.5 subject to Rule 16b-3 | 10/09/2024 |
5 | NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November | 10/28/2024 |
6 | NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results | 11/06/2024 |
7 | NewAmsterdams SWOT analysis obicetrapibs potential lifts stock outlook | 11/12/2024 |
8 | Disposition of 9832 shares by Forgrowth Nap B.v. of NewAmsterdam Pharma at 25.0057 subject to Rule 16b-3 | 11/14/2024 |
9 | Disposition of 33273 shares by Forgrowth Nap B.v. of NewAmsterdam Pharma at 25.0786 subject to Rule 16b-3 | 11/18/2024 |
10 | NewAmsterdam Pharma stock holds Overweight rating with catalysts ahead in Ph3 topline readouts | 11/19/2024 |
11 | Needham Company LLC Reiterates Buy Rating for NewAmsterdam Pharma - MarketBeat | 11/21/2024 |
12 | NewAmsterdam Pharma Trading Down 2.7 percent Heres What Happened | 11/29/2024 |
| Begin Period Cash Flow | 467.7 M |
NewAmsterdam |
NewAmsterdam Pharma Relative Risk vs. Return Landscape
If you would invest 1,591 in NewAmsterdam Pharma on September 1, 2024 and sell it today you would earn a total of 394.00 from holding NewAmsterdam Pharma or generate 24.76% return on investment over 90 days. NewAmsterdam Pharma is currently generating 0.4187% in daily expected returns and assumes 3.6605% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than NewAmsterdam, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
NewAmsterdam Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NewAmsterdam Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NewAmsterdam Pharma, and traders can use it to determine the average amount a NewAmsterdam Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1144
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NAMS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.66 actual daily | 32 68% of assets are more volatile |
Expected Return
| 0.42 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 9 91% of assets perform better |
Based on monthly moving average NewAmsterdam Pharma is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NewAmsterdam Pharma by adding it to a well-diversified portfolio.
NewAmsterdam Pharma Fundamentals Growth
NewAmsterdam Stock prices reflect investors' perceptions of the future prospects and financial health of NewAmsterdam Pharma, and NewAmsterdam Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NewAmsterdam Stock performance.
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (0.86) % | ||||
| Current Valuation | 1.5 B | ||||
| Shares Outstanding | 92.39 M | ||||
| Price To Book | 5.07 X | ||||
| Price To Sales | 57.20 X | ||||
| Revenue | 12.76 M | ||||
| EBITDA | (176.86 M) | ||||
| Net Income | (160.27 M) | ||||
| Total Debt | 60 K | ||||
| Book Value Per Share | 4.11 X | ||||
| Cash Flow From Operations | (141.22 M) | ||||
| Earnings Per Share | (2.21) X | ||||
| Market Capitalization | 2.29 B | ||||
| Total Asset | 347.1 M | ||||
| Retained Earnings | (316.97 M) | ||||
| Working Capital | 296.89 M | ||||
About NewAmsterdam Pharma Performance
Assessing NewAmsterdam Pharma's fundamental ratios provides investors with valuable insights into NewAmsterdam Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the NewAmsterdam Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.51) | (0.54) | |
| Return On Capital Employed | (0.56) | (0.53) | |
| Return On Assets | (0.51) | (0.54) | |
| Return On Equity | (0.61) | (0.58) |
Things to note about NewAmsterdam Pharma performance evaluation
Checking the ongoing alerts about NewAmsterdam Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NewAmsterdam Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NewAmsterdam Pharma had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 12.76 M. Net Loss for the year was (160.27 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NewAmsterdam Pharma generates negative cash flow from operations | |
| NewAmsterdam Pharma has a frail financial position based on the latest SEC disclosures | |
| Over 84.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: NewAmsterdam Pharma Trading Down 2.7 percent Heres What Happened |
- Analyzing NewAmsterdam Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NewAmsterdam Pharma's stock is overvalued or undervalued compared to its peers.
- Examining NewAmsterdam Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NewAmsterdam Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NewAmsterdam Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NewAmsterdam Pharma's stock. These opinions can provide insight into NewAmsterdam Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.